Eco Animal Health Group PLC
Company Profile
Business description
Eco Animal Health Group PLC is engaged in manufacturing and marketing animal health products. The company's product portfolio includes Aivlosin - macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry; Ecomectin, Eco heart, Ecotraz, and Ecomintic for treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry and cattle. The company's geographical segments include Corporate/UK, China & Japan, North America, South & South East Asia, Latin America, Europe, and the Rest of the World. Maximum revenue for the company is generated from China and Japan.
Contact
100 High street
The Grange
Southgate
LondonN14 6BN
GBRT: +44 2084478899
E: julia.trouse@ecoanimalhealth.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
227
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,853.70 | 60.20 | -0.76% |
| CAC 40 | 7,104.80 | 21.22 | -0.30% |
| DAX 40 | 20,374.10 | 188.63 | -0.92% |
| Dow JONES (US) | 40,185.60 | 591.94 | 1.50% |
| FTSE 100 | 7,964.18 | 50.93 | 0.64% |
| HKSE | 20,914.69 | 232.91 | 1.13% |
| NASDAQ | 16,670.64 | 283.33 | 1.73% |
| Nikkei 225 | 33,585.58 | 1,023.42 | -2.96% |
| NZX 50 Index | 12,019.13 | 182.30 | -1.49% |
| S&P 500 | 5,352.67 | 84.62 | 1.61% |
| S&P/ASX 200 | 7,646.50 | 63.10 | -0.82% |
| SSE Composite Index | 3,238.23 | 14.59 | 0.45% |